Alnylam Pharmaceuticals I... (ALNY)
Alnylam Pharmaceuticals Statistics
Share Statistics
Alnylam Pharmaceuticals has 130.07M shares outstanding. The number of shares has increased by 2.83% in one year.
| Shares Outstanding | 130.07M |
| Shares Change (YoY) | 2.83% |
| Shares Change (QoQ) | 0.85% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 124.35M |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 3.15M, so 2.44% of the outstanding shares have been sold short.
| Short Interest | 3.15M |
| Short % of Shares Out | 2.44% |
| Short % of Float | 2.46% |
| Short Ratio (days to cover) | 4.82 |
Valuation Ratios
The PE ratio is -108.78 and the forward PE ratio is 441.36. Alnylam Pharmaceuticals's PEG ratio is 2.82.
| PE Ratio | -108.78 |
| Forward PE | 441.36 |
| PS Ratio | 13.46 |
| Forward PS | 4.6 |
| PB Ratio | 451.03 |
| P/FCF Ratio | -710.48 |
| PEG Ratio | 2.82 |
Enterprise Valuation
Alnylam Pharmaceuticals Inc. has an Enterprise Value (EV) of 25.78B.
| EV / Earnings | -92.67 |
| EV / Sales | 11.47 |
| EV / EBITDA | -144.14 |
| EV / EBIT | -145.73 |
| EV / FCF | -605.28 |
Financial Position
The company has a current ratio of 2.78, with a Debt / Equity ratio of 19.32.
| Current Ratio | 2.78 |
| Quick Ratio | 2.71 |
| Debt / Equity | 19.32 |
| Total Debt / Capitalization | 95.08 |
| Cash Flow / Debt | -0.01 |
| Interest Coverage | -1.25 |
Financial Efficiency
Return on equity (ROE) is -4.15% and return on capital (ROIC) is -20.17%.
| Return on Equity (ROE) | -4.15% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | -20.17% |
| Revenue Per Employee | $1,008,180.72 |
| Profits Per Employee | $-124,734.08 |
| Employee Count | 2,230 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 4.12 |
Taxes
| Income Tax | 99.22M |
| Effective Tax Rate | -0.55 |
Stock Price Statistics
The stock price has increased by 76.18% in the last 52 weeks. The beta is 0.39, so Alnylam Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | 76.18% |
| 50-Day Moving Average | 260.11 |
| 200-Day Moving Average | 256.13 |
| Relative Strength Index (RSI) | 56.46 |
| Average Volume (20 Days) | 785.04K |
Income Statement
In the last 12 months, Alnylam Pharmaceuticals had revenue of 2.25B and earned -278.16M in profits. Earnings per share was -2.16.
| Revenue | 2.25B |
| Gross Profit | 1.92B |
| Operating Income | -176.88M |
| Net Income | -278.16M |
| EBITDA | -178.85M |
| EBIT | -176.88M |
| Earnings Per Share (EPS) | -2.16 |
Balance Sheet
The company has 127.13M in cash and 1.3B in debt, giving a net cash position of -1.17B.
| Cash & Cash Equivalents | 127.13M |
| Total Debt | 1.3B |
| Net Cash | -1.17B |
| Retained Earnings | 0 |
| Total Assets | 4.24B |
| Working Capital | 2.11B |
Cash Flow
In the last 12 months, operating cash flow was -8.31M and capital expenditures -34.28M, giving a free cash flow of -42.59M.
| Operating Cash Flow | -8.31M |
| Capital Expenditures | -34.28M |
| Free Cash Flow | -42.59M |
| FCF Per Share | -0.33 |
Margins
Gross margin is 85.62%, with operating and profit margins of -7.87% and -12.37%.
| Gross Margin | 85.62% |
| Operating Margin | -7.87% |
| Pretax Margin | -7.96% |
| Profit Margin | -12.37% |
| EBITDA Margin | -7.95% |
| EBIT Margin | -7.87% |
| FCF Margin | -1.89% |
Dividends & Yields
ALNY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.8% |
| FCF Yield | -0.12% |
Analyst Forecast
The average price target for ALNY is $322.5, which is 19.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $322.5 |
| Price Target Difference | 19.4% |
| Analyst Consensus | Buy |
| Analyst Count | 24 |
Scores
| Altman Z-Score | 3.56 |
| Piotroski F-Score | 4 |